Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

52.16 -0.91 (-1.71%)
Delayed Quote Updated: 1:26 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Pulse Bio (PLSE) Q3 2026 Earnings Call Transcript ↗
Pivotal AF study enrollment finished three months early on strong physician demand. 
Via The Motley Fool
Topics Earnings
News headline image
What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call ↗
Pulse Biosciences (NASDAQ:PLSE) said it completed enrollment ahead of schedule in the pivotal U.S. study of its nPulse Cardiac Catheter, setting up a data readout expected in the third quarter of 2027... 
Via MarketBeat
Topics Earnings
Pulse Biosciences (NASDAQ:PLSE) Posts Mixed Q3 2026 Results as NANOPULSE-AF Enrollment Completes ↗
Via Chartmill
News headline image
Why Pulse Biosciences Stock Popped Today ↗
The medical device maker now has a new bull touting its growth potential. 
Via The Motley Fool
Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024 ↗
Pulse Biosciences just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform ↗
Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President,... 
Via MarketBeat
Topics Intellectual Property
News headline image
Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript ↗
NANOPULSE-AF enrollment hit halfway point ahead of schedule with 82 patients. 
Via The Motley Fool
Topics Earnings
News headline image
Pulse Biosciences Q2 Earnings Call Highlights ↗
Pulse Biosciences (NASDAQ:PLSE) reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. ↗
Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pulse Biosciences Q1 Earnings Call Highlights ↗
Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new... 
Via MarketBeat
Topics Earnings
News headline image
PLSE Q1 2026 Earnings Transcript ↗
PLSE Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript ↗
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
PLSE Q4 2025 Earnings Transcript ↗
PLSE Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
These stocks have an unusual volume in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
Pulse Biosciences (PLSE) Earnings Transcript ↗
Pulse Biosciences (PLSE) Earnings Transcript 
Via The Motley Fool
News headline image
Pulse Biosciences Cash Jumps in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pulse Biosciences Inc (NASDAQ:PLSE) Reports Q2 2025 Earnings: Wider Loss, Clinical Progress in Focus ↗
Pulse Biosciences reported a Q2 2025 net loss of $0.28 per share, slightly wider than estimates, with no revenue. The company advances its nsPFA tech in clinical trials, focusing on atrial fibrillation... 
Via Chartmill
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns ↗
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts. 
Via Benzinga
Topics Economy
News headline image
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
S&P 500, Nasdaq Extend Record Highs; Dow Up Triple Digits ↗
The Dow Jones Industrial Average is up triple digits midday, as investors look ahead to this week's inflation data. 
Via Talk Markets
Topics Economy Stocks
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.